Evaluating Neurocrine Biosciences: Insights From 15 Financial Analysts
Portfolio Pulse from Benzinga Insights
Neurocrine Biosciences (NASDAQ:NBIX) has received varied analyst ratings over the past three months, with a general trend towards bullishness. Analysts have set a 12-month average price target of $174.87, reflecting a 5.85% increase from the previous target. The company has shown strong financial performance with a 30.37% revenue growth rate, a net margin of 11.01%, and a prudent debt management strategy.
August 19, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences has received predominantly bullish analyst ratings, with a 12-month average price target of $174.87, indicating a positive outlook. The company's strong financial performance, including a 30.37% revenue growth rate and a net margin of 11.01%, supports this optimism.
The majority of analysts have raised their ratings and price targets for NBIX, reflecting a positive sentiment. The company's strong financial metrics, such as high revenue growth and net margin, further bolster the bullish outlook. This combination of positive analyst sentiment and strong financial performance is likely to have a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100